Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.

Alimova I, Pierce A, Danis E, Donson A, Birks DK, Griesinger A, Foreman NK, Santi M, Soucek L, Venkataraman S, Vibhakar R.

Int J Cancer. 2019 Apr 15;144(8):1983-1995. doi: 10.1002/ijc.31873. Epub 2019 Jan 10.

PMID:
30230537
2.

Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.

Alimova I, Pierce AM, Harris P, Donson A, Birks DK, Prince E, Balakrishnan I, Foreman NK, Kool M, Hoffman L, Venkataraman S, Vibhakar R.

Oncotarget. 2017 Oct 19;8(57):97290-97303. doi: 10.18632/oncotarget.21932. eCollection 2017 Nov 14.

3.

The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.

Sechler M, Parrish JK, Birks DK, Jedlicka P.

Oncogene. 2017 Jul 20;36(29):4150-4160. doi: 10.1038/onc.2017.44. Epub 2017 Mar 20.

4.

Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors.

Mulcahy Levy JM, Zahedi S, Griesinger AM, Morin A, Davies KD, Aisner DL, Kleinschmidt-DeMasters BK, Fitzwalter BE, Goodall ML, Thorburn J, Amani V, Donson AM, Birks DK, Mirsky DM, Hankinson TC, Handler MH, Green AL, Vibhakar R, Foreman NK, Thorburn A.

Elife. 2017 Jan 17;6. pii: e19671. doi: 10.7554/eLife.19671.

5.

Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors.

Torchia J, Golbourn B, Feng S, Ho KC, Sin-Chan P, Vasiljevic A, Norman JD, Guilhamon P, Garzia L, Agamez NR, Lu M, Chan TS, Picard D, de Antonellis P, Khuong-Quang DA, Planello AC, Zeller C, Barsyte-Lovejoy D, Lafay-Cousin L, Letourneau L, Bourgey M, Yu M, Gendoo DMA, Dzamba M, Barszczyk M, Medina T, Riemenschneider AN, Morrissy AS, Ra YS, Ramaswamy V, Remke M, Dunham CP, Yip S, Ng HK, Lu JQ, Mehta V, Albrecht S, Pimentel J, Chan JA, Somers GR, Faria CC, Roque L, Fouladi M, Hoffman LM, Moore AS, Wang Y, Choi SA, Hansford JR, Catchpoole D, Birks DK, Foreman NK, Strother D, Klekner A, Bognár L, Garami M, Hauser P, Hortobágyi T, Wilson B, Hukin J, Carret AS, Van Meter TE, Hwang EI, Gajjar A, Chiou SH, Nakamura H, Toledano H, Fried I, Fults D, Wataya T, Fryer C, Eisenstat DD, Scheinemann K, Fleming AJ, Johnston DL, Michaud J, Zelcer S, Hammond R, Afzal S, Ramsay DA, Sirachainan N, Hongeng S, Larbcharoensub N, Grundy RG, Lulla RR, Fangusaro JR, Druker H, Bartels U, Grant R, Malkin D, McGlade CJ, Nicolaides T, Tihan T, Phillips J, Majewski J, Montpetit A, Bourque G, Bader GD, Reddy AT, Gillespie GY, Warmuth-Metz M, Rutkowski S, Tabori U, Lupien M, Brudno M, Schüller U, Pietsch T, Judkins AR, Hawkins CE, Bouffet E, Kim SK, Dirks PB, Taylor MD, Erdreich-Epstein A, Arrowsmith CH, De Carvalho DD, Rutka JT, Jabado N, Huang A.

Cancer Cell. 2016 Dec 12;30(6):891-908. doi: 10.1016/j.ccell.2016.11.003.

6.

Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma.

Prince EW, Balakrishnan I, Shah M, Mulcahy Levy JM, Griesinger AM, Alimova I, Harris PS, Birks DK, Donson AM, Davidson N, Remke M, Taylor MD, Handler MH, Foreman NK, Venkataraman S, Vibhakar R.

Oncotarget. 2016 Aug 16;7(33):53881-53894. doi: 10.18632/oncotarget.10692.

7.

Identification of targets for rational pharmacological therapy in childhood craniopharyngioma.

Gump JM, Donson AM, Birks DK, Amani VM, Rao KK, Griesinger AM, Kleinschmidt-DeMasters BK, Johnston JM, Anderson RC, Rosenfeld A, Handler M, Gore L, Foreman N, Hankinson TC.

Acta Neuropathol Commun. 2015 May 21;3:30. doi: 10.1186/s40478-015-0211-5.

8.

Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma.

Griesinger AM, Josephson RJ, Donson AM, Mulcahy Levy JM, Amani V, Birks DK, Hoffman LM, Furtek SL, Reigan P, Handler MH, Vibhakar R, Foreman NK.

Cancer Immunol Res. 2015 Oct;3(10):1165-74. doi: 10.1158/2326-6066.CIR-15-0061. Epub 2015 May 12.

9.

Microrna expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms.

Braoudaki M, Lambrou GI, Giannikou K, Milionis V, Stefanaki K, Birks DK, Prodromou N, Kolialexi A, Kattamis A, Spiliopoulou CA, Tzortzatou-Stathopoulou F, Kanavakis E.

J Hematol Oncol. 2014 Dec 31;7:96. doi: 10.1186/s13045-014-0096-y.

10.

Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors.

Levy JM, Thompson JC, Griesinger AM, Amani V, Donson AM, Birks DK, Morgan MJ, Mirsky DM, Handler MH, Foreman NK, Thorburn A.

Cancer Discov. 2014 Jul;4(7):773-80. doi: 10.1158/2159-8290.CD-14-0049. Epub 2014 May 13.

11.

Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.

Venkataraman S, Alimova I, Balakrishnan I, Harris P, Birks DK, Griesinger A, Amani V, Cristiano B, Remke M, Taylor MD, Handler M, Foreman NK, Vibhakar R.

Oncotarget. 2014 May 15;5(9):2355-71.

12.

Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.

Harris PS, Venkataraman S, Alimova I, Birks DK, Balakrishnan I, Cristiano B, Donson AM, Dubuc AM, Taylor MD, Foreman NK, Reigan P, Vibhakar R.

Mol Cancer. 2014 Mar 24;13:72. doi: 10.1186/1476-4598-13-72.

13.

Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma.

Hoffman LM, Donson AM, Nakachi I, Griesinger AM, Birks DK, Amani V, Hemenway MS, Liu AK, Wang M, Hankinson TC, Handler MH, Foreman NK.

Acta Neuropathol. 2014 May;127(5):731-45. doi: 10.1007/s00401-013-1212-8. Epub 2013 Nov 17.

14.

Pediatric brainstem gangliogliomas show BRAF(V600E) mutation in a high percentage of cases.

Donson AM, Kleinschmidt-DeMasters BK, Aisner DL, Bemis LT, Birks DK, Levy JM, Smith AA, Handler MH, Foreman NK, Rush SZ.

Brain Pathol. 2014 Mar;24(2):173-83. doi: 10.1111/bpa.12103. Epub 2013 Dec 23.

15.

Characterization of distinct immunophenotypes across pediatric brain tumor types.

Griesinger AM, Birks DK, Donson AM, Amani V, Hoffman LM, Waziri A, Wang M, Handler MH, Foreman NK.

J Immunol. 2013 Nov 1;191(9):4880-8. doi: 10.4049/jimmunol.1301966. Epub 2013 Sep 27.

16.

Insulin-like growth factor 2 mRNA binding protein 3 expression is an independent prognostic factor in pediatric pilocytic and pilomyxoid astrocytoma.

Barton VN, Donson AM, Birks DK, Kleinschmidt-DeMasters BK, Handler MH, Foreman NK, Rush SZ.

J Neuropathol Exp Neurol. 2013 May;72(5):442-9. doi: 10.1097/NEN.0b013e31829023dd.

17.

Epithelioid GBMs show a high percentage of BRAF V600E mutation.

Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK.

Am J Surg Pathol. 2013 May;37(5):685-98. doi: 10.1097/PAS.0b013e31827f9c5e.

18.

Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes.

Birks DK, Donson AM, Patel PR, Sufit A, Algar EM, Dunham C, Kleinschmidt-DeMasters BK, Handler MH, Vibhakar R, Foreman NK.

Pediatr Blood Cancer. 2013 Jul;60(7):1095-102. doi: 10.1002/pbc.24481. Epub 2013 Feb 4.

19.

MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma.

Venkataraman S, Birks DK, Balakrishnan I, Alimova I, Harris PS, Patel PR, Handler MH, Dubuc A, Taylor MD, Foreman NK, Vibhakar R.

J Biol Chem. 2013 Jan 18;288(3):1918-28. doi: 10.1074/jbc.M112.396762. Epub 2012 Dec 4.

20.

Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.

Alimova I, Birks DK, Harris PS, Knipstein JA, Venkataraman S, Marquez VE, Foreman NK, Vibhakar R.

Neuro Oncol. 2013 Feb;15(2):149-60. doi: 10.1093/neuonc/nos285. Epub 2012 Nov 28.

21.

Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells.

Whiteway SL, Harris PS, Venkataraman S, Alimova I, Birks DK, Donson AM, Foreman NK, Vibhakar R.

J Neurooncol. 2013 Jan;111(2):113-21. doi: 10.1007/s11060-012-1000-7. Epub 2012 Nov 9.

22.

Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish long-term from short-term survivors.

Donson AM, Birks DK, Schittone SA, Kleinschmidt-DeMasters BK, Sun DY, Hemenway MF, Handler MH, Waziri AE, Wang M, Foreman NK.

J Immunol. 2012 Aug 15;189(4):1920-7. doi: 10.4049/jimmunol.1103373. Epub 2012 Jul 16.

23.

Diffuse intrinsic pontine tumors: a study of primitive neuroectodermal tumors versus the more common diffuse intrinsic pontine gliomas.

Sufit A, Donson AM, Birks DK, Knipstein JA, Fenton LZ, Jedlicka P, Hankinson TC, Handler MH, Foreman NK.

J Neurosurg Pediatr. 2012 Aug;10(2):81-8. doi: 10.3171/2012.3.PEDS11316. Epub 2012 Jun 29.

24.

Clinical and molecular characteristics of congenital glioblastoma.

Macy ME, Birks DK, Barton VN, Chan MH, Donson AM, Kleinschmidt-Demasters BK, Bemis LT, Handler MH, Foreman NK.

Neuro Oncol. 2012 Jul;14(7):931-41. doi: 10.1093/neuonc/nos125. Epub 2012 Jun 18.

25.

Pediatric brainstem gangliogliomas show overexpression of neuropeptide prepronociceptin (PNOC) by microarray and immunohistochemistry.

Chan MH, Kleinschmidt-Demasters BK, Donson AM, Birks DK, Foreman NK, Rush SZ.

Pediatr Blood Cancer. 2012 Dec 15;59(7):1173-9. doi: 10.1002/pbc.24232. Epub 2012 Jun 15.

26.

Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.

Harris PS, Venkataraman S, Alimova I, Birks DK, Donson AM, Knipstein J, Dubuc A, Taylor MD, Handler MH, Foreman NK, Vibhakar R.

BMC Cancer. 2012 Mar 5;12:80. doi: 10.1186/1471-2407-12-80.

27.

Atypical teratoid rhabdoid tumors (ATRTs): the British Columbia's Children's Hospital's experience, 1986-2006.

Fleming AJ, Hukin J, Rassekh R, Fryer C, Kim J, Stemmer-Rachamimov A, Birks DK, Huang A, Yip S, Dunham C.

Brain Pathol. 2012 Sep;22(5):625-35. doi: 10.1111/j.1750-3639.2011.00561.x. Epub 2012 Feb 13.

PMID:
22188464
28.

Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells.

Knipstein JA, Birks DK, Donson AM, Alimova I, Foreman NK, Vibhakar R.

Neuro Oncol. 2012 Feb;14(2):175-83. doi: 10.1093/neuonc/nor208. Epub 2011 Dec 8.

29.

Atypical teratoid/rhabdoid tumor arising in a ganglioglioma: genetic characterization.

Kleinschmidt-DeMasters BK, Birks DK, Aisner DL, Hankinson TC, Rosenblum MK.

Am J Surg Pathol. 2011 Dec;35(12):1894-901. doi: 10.1097/PAS.0b013e3182382a3f.

PMID:
22082607
30.

High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival.

Birks DK, Donson AM, Patel PR, Dunham C, Muscat A, Algar EM, Ashley DM, Kleinschmidt-Demasters BK, Vibhakar R, Handler MH, Foreman NK.

Neuro Oncol. 2011 Dec;13(12):1296-307. doi: 10.1093/neuonc/nor140. Epub 2011 Sep 23.

31.

A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.

McKinsey EL, Parrish JK, Irwin AE, Niemeyer BF, Kern HB, Birks DK, Jedlicka P.

Oncogene. 2011 Dec 8;30(49):4910-20. doi: 10.1038/onc.2011.197. Epub 2011 Jun 6.

32.

Survey of MicroRNA expression in pediatric brain tumors.

Birks DK, Barton VN, Donson AM, Handler MH, Vibhakar R, Foreman NK.

Pediatr Blood Cancer. 2011 Feb;56(2):211-6. doi: 10.1002/pbc.22723. Epub 2010 Nov 3.

PMID:
21157891
33.

Aurora kinase A as a rational target for therapy in glioblastoma.

Barton VN, Foreman NK, Donson AM, Birks DK, Handler MH, Vibhakar R.

J Neurosurg Pediatr. 2010 Jul;6(1):98-105. doi: 10.3171/2010.3.PEDS10120.

PMID:
20593995
34.

Epithelioid versus rhabdoid glioblastomas are distinguished by monosomy 22 and immunohistochemical expression of INI-1 but not claudin 6.

Kleinschmidt-DeMasters BK, Alassiri AH, Birks DK, Newell KL, Moore W, Lillehei KO.

Am J Surg Pathol. 2010 Mar;34(3):341-54. doi: 10.1097/PAS.0b013e3181ce107b.

PMID:
20118769
35.

Immune gene and cell enrichment is associated with a good prognosis in ependymoma.

Donson AM, Birks DK, Barton VN, Wei Q, Kleinschmidt-Demasters BK, Handler MH, Waziri AE, Wang M, Foreman NK.

J Immunol. 2009 Dec 1;183(11):7428-40. doi: 10.4049/jimmunol.0902811. Epub 2009 Nov 16.

36.

Unique molecular characteristics of pediatric myxopapillary ependymoma.

Barton VN, Donson AM, Kleinschmidt-DeMasters BK, Birks DK, Handler MH, Foreman NK.

Brain Pathol. 2010 May;20(3):560-70. doi: 10.1111/j.1750-3639.2009.00333.x. Epub 2009 Sep 10.

37.

Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors.

Birks DK, Kleinschmidt-DeMasters BK, Donson AM, Barton VN, McNatt SA, Foreman NK, Handler MH.

Brain Pathol. 2010 Jan;20(1):140-50. doi: 10.1111/j.1750-3639.2008.00255.x. Epub 2009 Feb 9.

PMID:
19220299
38.

Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma.

Chen RW, Bemis LT, Amato CM, Myint H, Tran H, Birks DK, Eckhardt SG, Robinson WA.

Blood. 2008 Aug 1;112(3):822-9. doi: 10.1182/blood-2008-03-142182. Epub 2008 May 15.

39.

EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.

Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA Jr, Haney J, Helfrich BA, Kato H, Hirsch FR, Franklin WA.

Ann Oncol. 2008 Jun;19(6):1053-9. doi: 10.1093/annonc/mdn006. Epub 2008 Feb 27.

PMID:
18304967

Supplemental Content

Loading ...
Support Center